--------------------------------------------------------------------------------

Exhibit 10.18

[image00005.jpg]

Orly Mishan
 
Chief Business Officer

August 18, 2019

Dear Mark:
 
We are very pleased to extend you this offer of employment with Cerevel
Therapeutics, LLC (the “Company”). You will play a key role in the stand-up of
what we intend to be the preeminent Neuro/NeuroPsych drug development company
and we are excited about your joining the team.

The following are the basic terms of your proposed employment with the Company.
 

•
Position Title: Vice President, Finance and Chief Accounting Officer (reporting
to Kathy Yi, Chief Financial Officer)

 

•
Position Location: This position will be based in the Boston area.

•
Start Date: September 3, 2019.

•           Base Compensation: Your starting base compensation of $300,000
annually will be paid on a semi-monthly schedule (24 payrolls yearly) in the
gross amount of $12,500 per semi-monthly pay period. All payments shall be
subject to applicable deductions and withholdings, such as for payroll taxes.
 
•           Incentive Compensation: Your position is currently eligible to
participate in an annual cash incentive plan with a target of 25% of your base
compensation (pro-rated for a partial initial year of employment based on your
Start Date). Payment of incentive awards is based on the terms of the incentive
plan in effect for the year that such payment is being made. You must be
actively employed by the Company on the day incentives are paid to be eligible
to earn an incentive award. The Company reserves the right to alter or
discontinue its cash incentive plan in the future.
 
•           Benefits: Your position is eligible to participate in all employee
benefit plans from time to time in effect for employees of comparable status of
the Company. Your participation will be subject to the terms of the applicable
plan documents and generally applicable Company policies, as the same may be in
effect from time to time, and any other restrictions or limitations imposed by
law.
 
•          Equity Participation: Your position is eligible for participation in
the Cerevel Therapeutics, Inc. 2018 Equity Incentive Plan (the “Plan”). Subject
to the receipt of any required approvals and your continued employment through
the grant date, as soon as practicable following your Start Date, you will be
granted an option to purchase 40,385 shares of the Company’s common stock, which
as of the date of this letter, represents approximately 0.075% of the Company’s
fully diluted shares outstanding (the “Option”). The Option will have an
exercise price of not less than the fair market value of the Company’s common
stock on the date it is granted, as determined by the Company. The Option will
be evidenced by a form of stock option agreement and will be subject to the
terms of the Plan, the applicable stock option agreement, any other applicable
stockholders agreements, and any other restrictions and limitations generally
applicable to the common stock of the Company or equity awards held by the
Company’s executives or otherwise imposed by law. In the event of any conflict
between this letter and the terms of the stock option agreement or Plan, the
stock option agreement or Plan will control. In no event shall the Company or
any person affiliated with the Company have any liability with respect to the
failure of any compensation or benefits provided to you to be exempt from, or
comply with, Section 409A of the Internal Revenue Code.

Cerevel Therapeutics, LLC | 131 Dartmouth Street, Suite 502 | Boston,
Massachusetts 02116 | cerevel.com

--------------------------------------------------------------------------------

[image0.jpg]

•          Signing Bonus: Provided that you commence employment with the Company
by the Start Date, the Company will provide you with a one-time signing bonus of
$75,000 (the “Signing Bonus”). The Signing Bonus will be paid to you in a lump
sum on the next regular payday following the Start Date. In the event that your
employment with the Company is terminated for any reason other than by the
Company without Good Cause (as defined below) (i) before the twelve (12)-month
anniversary of the Start Date, you will repay to the Company the full amount of
any Signing Bonus or (ii) on or after the twelve (12)-month anniversary of the
Start Date but before the twenty-four (24)-month anniversary of the Start Date,
you shall repay to the Company fifty percent (50%) of the Signing Bonus. Any
repayment shall occur within thirty (30) days following the date of termination.
“Good Cause” shall mean the occurrence of any of the following, as determined by
the Company in its reasonable judgment: (i) your substantial failure to perform
(other than by reason of disability), or substantial negligence in the
performance of, your duties and responsibilities to the Company or any of its
affiliates; (ii) your material breach of this agreement or any other agreement
between you and the Company or any of its affiliates; (iii) your commission of,
or plea of nolo contendere to, a felony or other crime involving moral
turpitude; or (iv) other conduct by you that is or could reasonably be expected
to be materially harmful to the business interests or reputation of the Company
or any of its affiliates.
 
We are very excited to have you join our team and we look forward to a mutually
beneficial and rewarding relationship. However, we recognize that you will
retain the option, as will the Company, of ending your employment with the
Company at any time, with or without notice and with or without cause. As such,
your employment with the Company is at-will and neither this letter nor any
other oral or written representations may be considered a contract of employment
for any specific period of time.
 
You will be expected to devote your full business time and your best
professional efforts to the performance of your duties and responsibilities for
the Company and it affiliates and to abide by all policies and procedures of the
Company as in effect from time to time. You will be expected to perform the
duties of your position and such other duties as may be assigned to you from
time to time.
 
This offer is contingent upon the following:
 

•
Consenting to a background investigation, and upon the Company receiving results
of this investigation which it deems acceptable. Our background investigations
are performed in compliance with the Fair Credit Reporting Act.

 

•
Proper Documentation for Working in the United States. In accordance with the
Immigration Reform and Control Act of 1986, you must establish your eligibility
to work in the United States. On your first day of employment, please bring with
you and be prepared to show any of the acceptable forms of identification that
are outlined on the back of the INS Form I-9. The choice of identification to
show is yours.

•
Execution of the enclosed Restrictive Covenant Agreement on or before your Start
Date.

 
In accepting this offer, you give the Company assurance that you have not relied
on any agreements or representations, express or implied, with respect to your
employment that are not set forth expressly in this letter or the Restrictive
Covenant Agreement. You also give the Company assurance that you are not now
bound by any covenant against competition or other obligation that would be
violated by your acceptance of this offer or your employment by the Company
under it, or by your execution of the Restrictive Covenant Agreement.

Cerevel Therapeutics, LLC | 131 Dartmouth Street, Suite 502 | Boston,
Massachusetts 02116 | cerevel.com

--------------------------------------------------------------------------------

[image0.jpg]
 
Thank you for your interest in joining our team, and congratulations on your
offer. If you have any questions about this offer, please do not hesitate to
contact me . To accept this offer of employment. please sign and date the letter
below, and return it to my attention.
 
Sincerely,

/s/ Orly Mishan

Orly Mishan
Chief Business Officer

By my signature below, I hereby accept the offer of employment as set forth
above.
 

/s/ Mark Bodenrader
 
8/19/19
  Mark Bodenrader
 
Date
 

Cerevel Therapeutics, LLC | 131 Dartmouth Street, Suite 502 | Boston,
Massachusetts 02116 | cerevel.com

--------------------------------------------------------------------------------